Drug Profile
Dihydroergotamine - Impel Pharmaceuticals
Alternative Names: DHE; Dihydroergotamine Mesylate; INP-104; POD-DHE; TrudhesaLatest Information Update: 19 Jun 2023
Price :
$50
*
At a glance
- Originator Impel NeuroPharma
- Developer Impel Pharmaceuticals
- Class Antimigraines; Ergotamines; Mesylates; Small molecules
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Migraine
Most Recent Events
- 26 Apr 2023 Adverse events data from the phase III STOP 301 trial in Migraine presented at the Annual Meeting of American Academy of Neurology (AAN 2023)
- 25 Apr 2022 Impel Neuropharma is now called Impel Pharmaceuticals
- 30 Sep 2021 Planned Prescription Drug User Fee Act (PDUFA) date for Migraine in USA (Intranasal) is 2021-09-06